Helping Patients Access TREMFYA® (guselkumab)

REGISTER FOR UPDATES

Complete the registration form below to receive the latest updates from BioCoordiNATION™ as well as important information to support the treatment of your patients.

*Fields Required.

First Name*: *

Last Name*: *

Job Title:

E-mail Address*: *

Confirm E-mail Address*: *

Street Address*: *

State*: *

ZIP code *: *

Phone Number:

Yes, Janssen Biotech, Inc., may also send me information about other products and programs that may interest me.

Receive communications from Janssen Biotech, Inc.?

The information you provide will only be used by Janssen Biotech, Inc., our affiliates, and our service providers to send you information about TREMFYA® key resources and tools. You may unsubscribe here or by following the instructions in the messages you receive. Our Privacy Policy governs the use of the information you provide. By providing the information and selecting the “Submit” button, you indicate you read, understand, and agree to these terms.

Leave this field blank

Start Patients on TREMFYA® With iAssist^*

A streamlined, all-in-one web-based solution designed to help start patients on TREMFYA®

iAssist supports electronic prescribing, electronic prior authorizations and online access to the TREMFYA® PsO Simple Trial Program and other Janssen patient support programs.

LEARN MORE REGISTER WITH iASSIST

*AssistRx is a third-party technology solutions provider. iAssist is an AssistRx online platform to support the processes of prescribing and distributing prescription therapies, and connects patients to the services that support them throughout treatment.

Your One Source for Access, Affordability, and Treatment Support for Your Patients

Janssen CarePath helps verify insurance coverage for your patients, provides reimbursement information, helps find financial assistance options for eligible patients, and provides ongoing support to help them start and stay on TREMFYA® as prescribed.

Call a Janssen CarePath Care Coordinator at 877-CarePath (877-227-3728), Monday-Friday, 8 AM to 8 PM ET.

VISIT JANSSENCAREPATH.COM SIGN UP OR LOG IN TO THE PROVIDER PORTAL

Online Education for Biocoordinators

Imm-U-Knowledge is an innovative delivery platform for peer-to-peer education. Imm-U-Knowledge is designed to provide educational content and training to ensure biocoordinators understand the importance of biologics and their differences, enabling them to be more efficient in their jobs and more effective in ensuring patient access to medication.

TAKE A COURSE

CONTRAINDICATIONS
TREMFYA^® is contraindicated in patients with a history of serious hypersensitivity reaction to guselkumab or to any of the excipients.

WARNINGS AND PRECAUTIONS
Infections
TREMFYA^® may increase the risk of infection. Treatment with TREMFYA^® should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.

Consider the risks and benefits of treatment prior to prescribing TREMFYA^® in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving TREMFYA^® to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and discontinue TREMFYA^® until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis (TB)
Evaluate patients for TB infection prior to initiating treatment with TREMFYA^®. Initiate treatment of latent TB prior to administering TREMFYA^®. Monitor patients for signs and symptoms of active TB during and after TREMFYA^® treatment. Do not administer TREMFYA^® to patients with active TB infection.

Hypersensitivity Reactions
Serious hypersensitivity reactions have been reported with postmarket use of TREMFYA^®, some cases required hospitalization. If a serious hypersensitivity reaction occurs, discontinue TREMFYA^® and initiate appropriate therapy.

Immunizations
Prior to initiating TREMFYA^®, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with TREMFYA^®.

ADVERSE REACTIONS
Most common (≥1%) adverse reactions associated with TREMFYA^® include upper respiratory infections, headache, injection site reactions, arthralgia, diarrhea, gastroenteritis, tinea infections, and herpes simplex infections.

Please read the full Prescribing Information and Medication Guide for TREMFYA^®. Provide the Medication Guide to your patients and encourage discussion.

cp-82625v1

WELCOME TO
BioCoordiNATION^™:
The one destination for all the information and resources needed to help patients start and stay on TREMFYA^®

REGISTER FOR UPDATES

IMPORTANT SAFETY INFORMATION

INDICATION

Do you want to continue to [extlink:external-url]?

WELCOME TOBioCoordiNATION™:The one destination for all the information and resources needed to help patients start and stay on TREMFYA®

REGISTER FOR UPDATES

Do you want to continue to [extlink:external-url]?

WELCOME TO
BioCoordiNATION^™:
The one destination for all the information and resources needed to help patients start and stay on TREMFYA^®